Dimensional Fund Advisors LP Jounce Therapeutics, Inc. Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.9 - $1.85 $405,690 - $833,918	-450,767 Reduced 63.04%	264,270 $488,000
Q4 2022 Feb 09, 2023	SELL	$0.64 - $1.99 $186,629 - $580,301	-291,609 Reduced 28.97%	715,037 $793,000
Q3 2022 Nov 10, 2022	SELL	$2.73 - $4.92 $494,553 - $891,282	-181,155 Reduced 15.25%	1,006,646 $2.36 Million
Q2 2022 Aug 12, 2022	BUY	$2.8 - $7.67 $21,974 - $60,194	7,848 Added 0.67%	1,187,801 $3.6 Million
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $368,124 - $523,092	61,252 Added 5.48%	1,179,953 $8.01 Million
Q4 2021 Feb 09, 2022	BUY	$7.11 - $9.64 $505,919 - $685,943	71,156 Added 6.79%	1,118,701 $9.34 Million
Q3 2021 Nov 12, 2021	SELL	$5.04 - $8.73 $905,864 - $1.57 Million	-179,735 Reduced 14.64%	1,047,545 $7.78 Million
Q2 2021 Aug 12, 2021	BUY	$6.58 - $10.66 $1.1 Million - $1.78 Million	166,849 Added 15.73%	1,227,280 $8.35 Million
Q1 2021 May 14, 2021	SELL	$6.73 - $13.87 $785,000 - $1.62 Million	-116,642 Reduced 9.91%	1,060,431 $10.9 Million
Q4 2020 Feb 25, 2021	BUY	$6.37 - $10.33 $7.5 Million - $12.2 Million	1,177,073 New	1,177,073 $8.24 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.